Arcellx Inc (ACLX) Peer Comparison
$115.07
$0.00 (0.00%)As on 15-May-2026 16:00EDT
Market cap
$6,732 Mln
Revenue (TTM)
$22 Mln
P/E Ratio
--
P/B Ratio
16.7
Div. Yield
0 %
Edit
| Arcellx Inc (ACLX) | Terns Pharmaceuticals (TERN) | Galecto Inc (GLTO) | OpGen (OPGN) | |
|---|---|---|---|---|
Market cap ($ Mln) |
6,732 | 6,117 | 1,728 | 251 |
Revenue ($ Mln) |
22 | -- | -- | 5 |
Net Profit ($ Mln) |
-228.93 | -96.21 | -235.09 | 11.99 |
Net Margin (%) |
-1,027.25 | -- | -- | -87.52 |
RoE (%) |
-53.42 | -14.23 | -90.96 | 162.49 |
Price to Earnings |
-- | -- | -- | 137.50 |
Price-To-Book |
16.73 | 6.08 | 163.79 | 0.00 |
Income Statement ($ Mln)
| Arcellx Inc (ACLX) | Terns Pharmaceuticals (TERN) | Galecto Inc (GLTO) | OpGen (OPGN) | |
|---|---|---|---|---|
|
Operating Revenue
|
22.29 | 0.00 | 0.00 | 30.20 |
|
Cost of Revenue
|
6.68 | -- | 0.03 | 3.02 |
|
Gross Profit
|
15.61 | -- | -0.03 | 27.18 |
|
Operating Expenses
|
268.69 | 110.12 | 210.87 | 3.15 |
|
Operating Profit (EBIT)
|
-253.08 | -110.12 | -210.87 | 24.03 |
|
Other Income
|
-- | -- | -- | -- |
|
Profit before Tax
|
-228.87 | -95.63 | -209.79 | 24.43 |
|
Provision for Tax
|
0.07 | 0.58 | 0.05 | -0.81 |
|
Profit after Tax (Net Income)
|
-228.93 | -96.21 | -209.84 | 23.62 |
|
Minority Interest
|
-- | -- | -- | -- |
|
Consolidated Profit
|
-- | -- | -- | -- |
Liabilities ($ Mln)
| Arcellx Inc (ACLX) | Terns Pharmaceuticals (TERN) | Galecto Inc (GLTO) | OpGen (OPGN) | |
|---|---|---|---|---|
|
Shareholder's Funds
|
402.35 | 1,006.52 | 240.38 | 31.86 |
|
Minority Interest
|
-- | -- | -- | -- |
|
Non-Current Liabilities
|
97.44 | 2.14 | 0.08 | 1.65 |
|
Current Liabilities
|
104.20 | 16.41 | 20.07 | 4.55 |
|
Total Liabilities
|
603.99 | 1,025.08 | 260.53 | 38.06 |
Assets ($ Mln)
| Arcellx Inc (ACLX) | Terns Pharmaceuticals (TERN) | Galecto Inc (GLTO) | OpGen (OPGN) | |
|---|---|---|---|---|
|
Non-Current Assets
|
141.81 | 0.88 | 0.10 | 37.07 |
|
Current Assets
|
462.18 | 1,024.19 | 260.42 | 0.99 |
|
Total Assets
|
603.99 | 1,025.08 | 260.53 | 38.06 |
|
Total Debt*
|
96.26 | 0.92 | 0.07 | 1.85 |
|
Net Current Assets
|
357.98 | 1,007.78 | 240.36 | -- |
Cashflow ($ Mln)
| Arcellx Inc (ACLX) | Terns Pharmaceuticals (TERN) | Galecto Inc (GLTO) | OpGen (OPGN) | |
|---|---|---|---|---|
|
Cash From Operating Activities
|
-210.26 | -82.18 | -6.73 | -1.18 |
|
Cash Flow from Investing Activities
|
86.30 | -298.04 | -17.37 | -0.05 |
|
Cash from Financing Activities
|
98.53 | 743.51 | 266.84 | 0.50 |
|
Net Cash Inflow / Outflow
|
-- | -- | -- | -- |
Ratios
Profitability Ratios
| Arcellx Inc (ACLX) | Terns Pharmaceuticals (TERN) | Galecto Inc (GLTO) | OpGen (OPGN) | |
|---|---|---|---|---|
|
ROCE (%)
|
-45.45 | -14.20 | -163.71 | 114.98 |
|
ROE (%)
|
-53.42 | -14.23 | -163.80 | 120.40 |
|
ROA (%)
|
-34.81 | -13.85 | -151.15 | 98.59 |
|
EBIT Margin (%)
|
-- | -- | -- | -- |
|
Net Margin (%)
|
-1,027.25 | -- | -- | 78.21 |
|
Cash Profit Margin (%)
|
-- | -- | -- | -- |
Growth Ratios
| Arcellx Inc (ACLX) | Terns Pharmaceuticals (TERN) | Galecto Inc (GLTO) | OpGen (OPGN) | |
|---|---|---|---|---|
|
Revenue Growth (%)
|
-0.79 | -- | -- | 4.81 |
|
EBIT Growth (%)
|
-- | -- | -- | -- |
|
Net Profit Growth (%)
|
-113.26 | -8.28 | -878.77 | 96.95 |
|
EPS Growth (%)
|
-1.03 | -0.06 | -6.09 | 0.97 |
|
Book Value Growth (%)
|
-- | -- | -- | -- |
Valuation Ratios
| Arcellx Inc (ACLX) | Terns Pharmaceuticals (TERN) | Galecto Inc (GLTO) | OpGen (OPGN) | |
|---|---|---|---|---|
|
Price / Earnings
|
-16.04 | -39.12 | -0.18 | -- |
|
Price / Book Value
|
9.12 | 3.74 | 0.15 | -- |
|
Dividend Yield (%)
|
-- | -- | -- | -- |
|
EV/EBITDA
|
-16.76 | -24.93 | 1.05 | -- |
|
Market Cap ($ Cr)
|
-- | -- | -- | -- |
Solvency Ratios
| Arcellx Inc (ACLX) | Terns Pharmaceuticals (TERN) | Galecto Inc (GLTO) | OpGen (OPGN) | |
|---|---|---|---|---|
|
Debt to Equity
|
0.24 | 0.00 | 0.00 | 0.06 |
|
Short term debt to equity ratio
|
0.02 | 0.00 | 0.00 | 0.01 |
|
Current Ratio
|
4.44 | 62.41 | 12.98 | 0.22 |
|
Quick Ratio
|
-- | -- | -- | -- |
|
Interest Coverage
|
-8.45 | -- | -- | 0.00 |
Operating Efficiency Ratios
| Arcellx Inc (ACLX) | Terns Pharmaceuticals (TERN) | Galecto Inc (GLTO) | OpGen (OPGN) | |
|---|---|---|---|---|
|
Debtors to sales (%)
|
16.15 | -- | -- | 0.82 |
|
Asset Turnover
|
0.03 | 0.00 | 0.00 | 1.26 |
|
Receivable days
|
59.00 | -- | -- | 1.68 |
|
Inventory Days
|
-- | -- | -- | -- |
|
Payable days
|
209.78 | -- | 4,409.86 | 80.25 |
|
Cash Conversion Cycle
|
-- | -- | -- | -- |
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
